A Phase 2/3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of BNT162b2 RNABased Vaccine Candidates for SARS-CoV-2 New Variants in Healthy Individuals Substudy C

A Phase 2/3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of BNT162b2 RNABased Vaccine Candidates for SARS-CoV-2 New Variants in Healthy Individuals Substudy C chavak11 Thu, 03/05/2026 - 04:34 Comirnaty® PF-07302048 (BNT162b2) PHASE II/III Thu, 08/10/2023 - 12:00 Thu, 03/13/2025 - 12:00 NCT05997290 C4591054 SSC Final Public Disclosure Synopsis.pdf (120.97 KB) N https://clinicaltrials.gov/study/NCT05997290?term=C4591054&rank=1 C4591054